ZA201907158B - Methods and compositions for treating sleep apnea - Google Patents

Methods and compositions for treating sleep apnea

Info

Publication number
ZA201907158B
ZA201907158B ZA2019/07158A ZA201907158A ZA201907158B ZA 201907158 B ZA201907158 B ZA 201907158B ZA 2019/07158 A ZA2019/07158 A ZA 2019/07158A ZA 201907158 A ZA201907158 A ZA 201907158A ZA 201907158 B ZA201907158 B ZA 201907158B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
sleep apnea
treating sleep
treating
Prior art date
Application number
ZA2019/07158A
Other languages
English (en)
Inventor
D Andrew Wellman
Luigi Taranto-Montemurro
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201907158(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Publication of ZA201907158B publication Critical patent/ZA201907158B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2019/07158A 2017-04-28 2019-10-29 Methods and compositions for treating sleep apnea ZA201907158B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US201762558814P 2017-09-14 2017-09-14
PCT/US2018/029518 WO2018200775A1 (en) 2017-04-28 2018-04-26 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
ZA201907158B true ZA201907158B (en) 2021-09-29

Family

ID=63918622

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/07158A ZA201907158B (en) 2017-04-28 2019-10-29 Methods and compositions for treating sleep apnea

Country Status (21)

Country Link
US (5) US11123313B2 (cg-RX-API-DMAC7.html)
EP (1) EP3615016A4 (cg-RX-API-DMAC7.html)
JP (3) JP7373997B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250145704A (cg-RX-API-DMAC7.html)
CN (2) CN119185558A (cg-RX-API-DMAC7.html)
AU (3) AU2018260666B2 (cg-RX-API-DMAC7.html)
CA (1) CA3061468A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013180A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190546A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000274A (cg-RX-API-DMAC7.html)
EC (1) ECSP19084058A (cg-RX-API-DMAC7.html)
GE (6) GEAP202416602A (cg-RX-API-DMAC7.html)
MA (1) MA49069A (cg-RX-API-DMAC7.html)
MX (2) MX394941B (cg-RX-API-DMAC7.html)
MY (1) MY200172A (cg-RX-API-DMAC7.html)
NI (1) NI201900110A (cg-RX-API-DMAC7.html)
PH (1) PH12019502427A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201909973UA (cg-RX-API-DMAC7.html)
UA (1) UA127759C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018200775A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201907158B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119185558A (zh) * 2017-04-28 2024-12-27 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
WO2019245975A1 (en) 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
CA3117766A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
ES3049086T3 (en) * 2019-02-08 2025-12-12 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
US12616702B2 (en) 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP4146621A1 (en) 2020-05-05 2023-03-15 Apnimed, Inc. (Delaware) Polymorphic forms of (r)-oxybutynin hydrochloride
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CA3210092A1 (en) * 2021-03-04 2022-09-09 Lawrence G. Miller Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
CN117177741A (zh) * 2021-04-16 2023-12-05 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合
JP2024523876A (ja) * 2021-06-17 2024-07-02 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤
JP2024534173A (ja) * 2021-08-31 2024-09-18 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するための方法及び組成物
CA3259602A1 (en) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea
MX2024007768A (es) 2021-12-22 2024-07-01 Bayer Ag Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o.
IL313648A (en) * 2021-12-22 2024-08-01 Bayer Ag Combination of a TASK1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
EP4522149A1 (en) * 2022-05-13 2025-03-19 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
US20260041659A1 (en) * 2024-08-07 2026-02-12 Yogesh Dandiker Topical atomoxetine and oxybutynin for obstructive sleep apnea
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2006023703A2 (en) 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
JP2008524332A (ja) * 2004-12-20 2008-07-10 コレジウム ファーマシューティカル, インク. 睡眠傷害のための医薬組成物
CN107007602A (zh) * 2011-01-28 2017-08-04 辉达斯医学研究所 治疗阻塞性睡眠呼吸暂停的方法
CN119185558A (zh) * 2017-04-28 2024-12-27 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物

Also Published As

Publication number Publication date
PH12019502427A1 (en) 2020-10-05
WO2018200775A1 (en) 2018-11-01
DOP2019000274A (es) 2019-12-30
GEAP202416602A (en) 2024-10-10
BR112019022483A2 (pt) 2020-05-12
MX2022010349A (es) 2022-09-19
MX394941B (es) 2025-03-24
AU2018260666A1 (en) 2019-11-14
MY200172A (en) 2023-12-12
US11123313B2 (en) 2021-09-21
CR20190546A (es) 2020-04-08
ECSP19084058A (es) 2020-01-31
US20240189261A1 (en) 2024-06-13
NZ758564A (en) 2023-12-22
EP3615016A1 (en) 2020-03-04
GEP20227387B (en) 2022-06-10
SG10202111623TA (en) 2021-12-30
CN119185558A (zh) 2024-12-27
AU2018260666B2 (en) 2022-07-21
KR20250145704A (ko) 2025-10-13
US20240261239A1 (en) 2024-08-08
US20210401777A1 (en) 2021-12-30
UA127759C2 (uk) 2023-12-27
US20260007618A1 (en) 2026-01-08
CN110799181A (zh) 2020-02-14
US20200054583A1 (en) 2020-02-20
GEP20257788B (en) 2025-08-25
AU2025230729A1 (en) 2025-10-02
JP2023139000A (ja) 2023-10-03
CA3061468A1 (en) 2018-11-01
SG11201909973UA (en) 2019-11-28
GEP20247617B (en) 2024-04-25
JP2025169279A (ja) 2025-11-12
NI201900110A (es) 2020-03-18
KR20240042261A (ko) 2024-04-01
MX2019012729A (es) 2019-12-19
GEAP202316320A (en) 2023-09-11
MA49069A (fr) 2020-03-04
KR102682159B1 (ko) 2024-07-08
EP3615016A4 (en) 2021-02-24
GEAP202115226A (en) 2021-12-27
KR20190140019A (ko) 2019-12-18
JP7373997B2 (ja) 2023-11-06
AU2022241471A1 (en) 2022-10-27
CO2019013180A2 (es) 2020-02-07
JP2020517719A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
IL276247A (en) Methods and materials for the treatment of sleep apnea
IL271503A (en) Preparations and treatments for sleep disorders
IL269620A (en) Preparations and methods for the treatment of phenylketonuria
IL260257A (en) Compositions and methods for the treatment of hemoglobinopathies
PL3253443T3 (pl) Urządzenie do leczenia chrapania i bezdechu sennego
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
EP3092033A4 (en) Method and apparatus for treating sleep apnea
IL269637A (en) Preparations and methods for the treatment of synovial diseases
IL246537A0 (en) Apparatus and method for treating sleep apnea
IL285197A (en) Methods and preparations for the treatment of sleep apnea
IL271256A (en) Preparations and methods for the treatment of teopathy
LT3691649T (lt) Žaizdų gydymo kompozicijos ir būdai
EP3148488A4 (en) Oral appliance for treating sleep apnea
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
EP3624808A4 (en) PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
IL251881A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
ZA202002526B (en) New alcoxyamino derivatives for treating pain and pain related conditions
ZA201806320B (en) Sultiame for the treatment of sleep apnea
IL235257A (en) Snoring and sleep apnea system
GB201913589D0 (en) Systems and methods for reducing snoring and/or sleep apnea
HK40017009A (en) Methods and compositions for treating sleep apnea
HK40059516A (en) Methods and compositions for treating sleep apnea
SG11202104661WA (en) Composition and method for aiding sleep
AU2017902338A0 (en) Sleep Disorder Composition and Treatment Thereof
GB201521083D0 (en) Compositions for treatment and methods thereof